Author/Authors :
Totonchi، Ziae نويسنده Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran , , Rezvani، Hengameh نويسنده Iran University of Medical Sciences, Tehran, IR
Iran , , Ghorbanloo، Masoud نويسنده Hasheminejad Kidney Center, Iran University of Medical
Sciences, Tehran, IR Iran , , Yazdanian، Forouzan نويسنده , , Mahdavi، Mohammad نويسنده , , Babaali، Nima نويسنده Department of Cardiology, Rajaei Cardiovascular, Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran , , Salajegheh، Shirin نويسنده Kerman University of Medical Sciences, Kerman, IR
Iran , , Chitsazan، Mitra نويسنده Student Scientific Research Committee, Tehran University of Medical Sciences,Tehran, Iran. ,
Abstract :
Infants and children compared with adults have intensified stress
responses that lead to increased morbidity and mortality. Stress control
reduces the incidence of complications and improves recovery. In
clinical and experimental studies, dexmedetomidine reduces the
inflammatory and neuroendocrine responses. This prospective randomized
double-blinded clinical trial was conducted to assess the role of
dexmedetomidine in reducing stress responses. According to convenient
sampling method, 40 patients in two groups (case under treatment with
dexmedetomidine and control, each including 20 patients) were selected
from whom admitted for open heart surgery. Anesthesia was induced and
maintained by fentanyl and midazolam. After central venous and arterial
catheter insertion, patients were randomly allocated into one of two
equal groups (n = 20 each). In the dexmedetomidine group, patients
received an initial loading dose (0.5 μg/kg) during 10 minutes
immediately followed by a continuous infusion of 0.5 μg/kg. In the
control group, normal saline solution with similar volume was infused.
Changes in heart rate, systolic and diastolic blood pressures and
central venous pressure before administration of dexmedetomidine, in 10,
20 and 30 minutes after the operation, after skin incision, after
sternotomy, after separation from the pump and at the end of procedure
showed no significant difference between the two groups (P = 0.860,
0.067, 0.888 and 0.482, respectively). Changes in lactate, interleukin
6, tumor necrosis factor, C-reactive protein concentrations before
administration of dexmedetomidine, after separation of pump and 24 hours
after intensive care unit entrance showed no significant difference
between the two groups (P = 0.525, 0.767, 0.868 and 0.840,
respectively). According to our findings, using dexmedetomidine as an
adjuvant anesthetic medication with initial loading dose of 0.5 μg/kg
and maintenance dose of 0.5 μg /kg in pediatric heart surgeries is a
safe choice. However, further studies are needed to clarify the role of
dexmedetomidine to reduce stress responses.